<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9359">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05699655</url>
  </required_header>
  <id_info>
    <org_study_id>TAOS-3B Trial 2</org_study_id>
    <nct_id>NCT05699655</nct_id>
  </id_info>
  <brief_title>Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer</brief_title>
  <official_title>Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer: Randomized Control, Open, Multicenter Trial-2 (TAOS-3B-Trial-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fujian Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the clinical efficacy and safety of Tislelizumab combined with apatinib mesylate,&#xD;
      oxaliplatin plus S1 Vs oxaliplatin plus S1.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2023</start_date>
  <completion_date type="Anticipated">April 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2025</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological complete response</measure>
    <time_frame>4 weeks after surgery</time_frame>
    <description>Total tumor regression rate under pathologyPrimary tumor or lymph node surgery specimen pathological examination without residual tumor cell</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major pathological response</measure>
    <time_frame>4 weeks after surgery</time_frame>
    <description>Total/moderate tumor regression rate under pathologyPrimary tumor or lymph node surgery specimen pathological examination without residual tumor cell</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>At the end of Cycle 3 (each cycle is 21 days)]</time_frame>
    <description>Objective Response Rate Determine the tumor shrinkage rate, tumor boundary and the adhesion of tumor</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Immunotherapy Gastrict Cancer</condition>
  <arm_group>
    <arm_group_label>Tislelizumab combined with apatinib and oxaliplatin plus S1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>oxaliplatin plus S1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tislelizumab</intervention_name>
    <description>Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 4 cycles. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.</description>
    <arm_group_label>Tislelizumab combined with apatinib and oxaliplatin plus S1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>apatinib</intervention_name>
    <description>Participants will receive apatinib, 250mg, qd，every 3 weeks for 3 weeks</description>
    <arm_group_label>Tislelizumab combined with apatinib and oxaliplatin plus S1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
    <description>Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 4 weeks.</description>
    <arm_group_label>Tislelizumab combined with apatinib and oxaliplatin plus S1</arm_group_label>
    <arm_group_label>oxaliplatin plus S1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1</intervention_name>
    <description>Participants will receive S-1, day 1-14 of every 3 weeks for 4 weeks.</description>
    <arm_group_label>Tislelizumab combined with apatinib and oxaliplatin plus S1</arm_group_label>
    <arm_group_label>oxaliplatin plus S1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18-70 years of age.&#xD;
&#xD;
          -  Histologically confirmed gastric adenocarcinoma was diagnosed in patients with locally&#xD;
             advanced gastric cancer with tumor volume &gt;5cm Borrmann III, Borrmann IV and BulkyN&#xD;
             according to AJCC Version 8.&#xD;
&#xD;
          -  Measurable lesions at least should be detected by CT/MRI examination in accordance&#xD;
             with the RECIST1.1.&#xD;
&#xD;
          -  ECOG（Eastern Cooperative Oncology Group）PS（Performance Status）:0-1 scores.&#xD;
&#xD;
          -  No previous surgical treatment, anti-tumor chemoradiotherapy/immunotherapy was&#xD;
             performed.&#xD;
&#xD;
          -  Preoperative endoscopic examination confirmed no positive peritoneal implantation&#xD;
             metastasis and exfoliated cells.&#xD;
&#xD;
          -  The expected survival time is more than 6 months.&#xD;
&#xD;
          -  For women of reproductive age, a urine or serum pregnancy test with negative results&#xD;
             should be performed within 3 days prior to receiving the first study drug&#xD;
             administration (day 1 of cycle 1).If a urine pregnancy test result cannot be confirmed&#xD;
             as negative, a blood pregnancy test is requested.Women of childbearing age were&#xD;
             defined as at least 1 year after menopause or having undergone surgical sterilization&#xD;
             or hysterectomy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of malignant diseases other than gastric cancer within 5 years prior to&#xD;
             first administration (excluding radical basal cell carcinoma of the skin, squamous&#xD;
             carcinoma of the skin, and/or radical resectable carcinoma in situ).&#xD;
&#xD;
          -  Significant clinical bleeding symptoms or clear bleeding tendency, such as&#xD;
             gastrointestinal bleeding, hemorrhagic gastric ulcer or vasculitis, etc. occurred&#xD;
             within 3 months before enrollment. If fecal occult blood was positive at baseline,&#xD;
             reexamination could be performed，if it was still positive after reexamination,&#xD;
             gastroscopy was required.&#xD;
&#xD;
          -  Prior treatment: anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs or drugs that target&#xD;
             another stimulating or co-inhibiting T-cell receptor (e.g., CTLA-4, OX-40, CD137).&#xD;
&#xD;
          -  A history of immunodeficiency, including HIV testing positive.&#xD;
&#xD;
          -  Is currently participating in an interventional clinical study or has been treated&#xD;
             with another study drug or study device in the 4 weeks prior to initial dosing.&#xD;
&#xD;
          -  Patients who had a history of cardiovascular and cerebrovascular diseases and were&#xD;
             still taking thrombolytic drugs or anticoagulants orally.&#xD;
&#xD;
          -  HER2 positive is known.&#xD;
&#xD;
          -  Patients with previous gastrointestinal perforation, abdominal abscess or recent&#xD;
             intestinal obstruction (within 3 months) or imaging or clinical symptoms suggesting&#xD;
             intestinal obstruction.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>chen lu chuan, bachelor</last_name>
    <phone>13905022862</phone>
    <phone_ext>86</phone_ext>
    <email>Luchuanchen@sina.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ye Z sheng, Doctor of Medicine</last_name>
    <phone>13950203076</phone>
    <phone_ext>86</phone_ext>
    <email>flyingengel@sina.cn</email>
  </overall_contact_backup>
  <verification_date>January 2023</verification_date>
  <study_first_submitted>January 17, 2023</study_first_submitted>
  <study_first_submitted_qc>January 17, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 26, 2023</study_first_posted>
  <last_update_submitted>January 17, 2023</last_update_submitted>
  <last_update_submitted_qc>January 17, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Apatinib</mesh_term>
    <mesh_term>Tislelizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

